---
created: 2025-04-13
updated: 2025-04-13T10:53
id: M3DTgwU(U!
specialty: immuno
specialty_id: 122
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::dupilumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::dupilumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::immunology-&-biochemistry-pharmacology::immuno-suppressives::general-immunotherapy
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary"
type: flashcard
---

# Question
Dupilumab is a monoclonal antibody against the **IL4** receptor alpha subunit

---

# Answer
This allows it to block both the IL-4 and IL-13 receptors (both use the IL-4R alpha chain)